May 22, 2013
Salix Pharmaceuticals Announces Statistically Significant Results For Budesonide Foam In The Treatment Of Active Mild To Moderate Ulcerative Proctitis Or Ulcerative Proctosigmoiditis In Two Pivotal Phase 3 Studies
May 17, 2013
Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013
May 09, 2013
Salix Pharmaceuticals Reports 1Q2013 Results
May 07, 2013
Salix Pharmaceuticals To Present At BofA Merrill Lynch 2013 Health Care Conference
April 25, 2013
Salix Pharmaceuticals Announces 1Q2013 Financial Results Conference Call And Webcast
March 05, 2013
Salix Pharmaceuticals Reports 4Q2012 And FY2012 Results
March 05, 2013
Salix Pharmaceuticals To Present At Two Investment Conferences In March
March 05, 2013
Salix Pharmaceuticals Announces 4Q2012 And Fy2012 Financial Results Conference Call And Webcast
January 02, 2013
Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference
January 02, 2013
FDA Approves Fulyzaq™ (Crofelemer) 125 mg Delayed-Release Tablets For The Symptomatic Relief Of Diarrhea In Patients With HIV/AIDS On Anti-Retroviral Therapy (ART)
November 09, 2012
Salix Pharmaceuticals Previews The American Association For The Study Of Liver Diseases 2012
November 07, 2012
Salix Pharmaceuticals Reports 3Q2012 Results
November 07, 2012
Salix Pharmaceuticals To Present At Two Investment Conferences In November
October 24, 2012
Salix Pharmaceuticals Announces 3Q2012 Financial Results Conference Call And Webcast
October 19, 2012
New Documentary, “Wrestling the Monster: Living with Hepatic Encephalopathy,” Premieres at American College of Gastroenterology 2012 Scientific Meeting
October 19, 2012
Salix Pharmaceuticals Previews American College Of Gastroenterology 2012
September 05, 2012
Salix Pharmaceuticals Outlines Data Presentations At PAINWeek
September 05, 2012
FDA Continues Review Of Crofelemer New Drug Application Beyond PDUFA Goal Date Of September 5, 2012
August 08, 2012
Salix Pharmaceuticals And Alfa Wassermann Announce License Agreement For A New Extended Intestinal Release Formulation Of Rifaximin
August 08, 2012
Salix Pharmaceuticals Reports 2Q2012 Results
July 27, 2012
Salix And Progenics Receive Complete Response Letter From FDA For Relistor® sNDA
July 25, 2012
Salix Pharmaceuticals Announces 2Q2012 Financial Results Conference Call And Webcast
May 29, 2012
Salix Pharmaceuticals To Present At Three Investment Conferences In June
May 18, 2012
Salix Pharmaceuticals Outlines Data Presentations At Digestive Disease Week 2012
May 07, 2012
Salix Pharmaceuticals Reports 1Q2012 Results